{
  "docId": "019de072-8046-72ee-8797-71c9ff7422eb",
  "docSlug": "98d74c454dfdfefd8fb9993ff5213b70",
  "documentTitle": "Hillevax | IPO Presentation Deck | 24 slides",
  "authorId": "hillevax",
  "authorName": "Hillevax",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 16,
  "pageCount": 24,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "The chart compares cross-study data for infants, adults, and older adults, demonstrating sustained titers above baseline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-8046-72ee-8797-71c9ff7422eb/16",
  "deckHref": "/decks/019de072-8046-72ee-8797-71c9ff7422eb",
  "deckJsonHref": "/decks/019de072-8046-72ee-8797-71c9ff7422eb.json",
  "deckAnchorHref": "/decks/019de072-8046-72ee-8797-71c9ff7422eb#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.55,
        "x": 0.36,
        "y": 0.15
      },
      "kind": "chart",
      "text": "GII.4 HBGA blocking titers over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a00e3b0-75ba-44aa-b8f2-3241bea378c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "HBGA is an attachment factor on the surface of intestinal epithelia known to promote norovirus entry into host cells. Measurement of HBGA-blocking antibodies is the primary method to assess vaccine immunogenicity against norovirus. Interim data from ongoing long-term immunogenicity study in adults (NOR-213) has shown titers to date above baseline at year 3",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fd184e8-5902-4def-9e85-6b3675f3e6af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.36,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. Day 0 titers were collected 28 days prior to vaccination for adult study (NOR-107)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41f3c8f6-1c7a-44ce-a13c-00bcaf829edd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.36,
        "y": 0.06
      },
      "kind": "title",
      "text": "HBGA blocking response following vaccination with HIL-214",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68ff6c5e-4470-4e5c-9921-3349a84b5fdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.25,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "HIL-214 IMMUNOGENICITY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72d9b362-edeb-4087-9fe3-b6dbb43361a6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 13,
      "beatId": "203d2e43-a365-49ec-802a-f481a270533f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 13-16 present clinical data supporting HIL-214's efficacy and safety",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}